• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Feb 12, 2009
    Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
  • Jan 21, 2009
    Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
  • Dec 26, 2008
    Insmed to Appeal Delisting Notification From Nasdaq
  • Dec 23, 2008
    Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule
  • Nov 25, 2008
    Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
  • Nov 18, 2008
    Insmed to Participate in Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation
  • Nov 10, 2008
    Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs
  • Nov 5, 2008
    Insmed to Present at Upcoming Healthcare Conferences
  • Oct 30, 2008
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
    • Photos 4
  • Oct 22, 2008
    NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009
  • Oct 21, 2008
    Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
  • Oct 20, 2008
    Insmed to Host Third Quarter 2008 Conference Call
  • Oct 14, 2008
    Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
  • Oct 14, 2008
    Insmed to Seek Shareholder Approval for Reverse Split
  • Sep 23, 2008
    Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
  • Sep 15, 2008
    Insmed to Present at Biosimilars 2008 Conference
  • Sep 4, 2008
    Insmed to Present at BioPharm Asia 2008 Conference
  • Sep 3, 2008
    NASDAQ Hearing Panel Grants Insmed Request for Continued Listing on the NASDAQ Stock Market
  • Aug 8, 2008
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
  • Jul 28, 2008
    Jim Miller, Ph.D. Joins Insmed Therapeutic Proteins as Vice President of Process Development
  • Jul 25, 2008
    Insmed to Host Second Quarter 2008 Conference Call
  • Jul 25, 2008
    Insmed CEO to Present at Drug Discovery & Development Conference
  • Jul 22, 2008
    Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
  • Jul 21, 2008
    Insmed Provides Update on IPLEX(TM) Programs
  • Jul 17, 2008
    Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
  • Jul 14, 2008
    Insmed Retains RBC Capital Markets as Strategic Financial Advisor
  • Jul 10, 2008
    Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
  • Jul 9, 2008
    Insmed to Present at Collins Stewart Fourth Annual Growth Conference
  • Jun 20, 2008
    Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
  • May 8, 2008
    Insmed Announces First Quarter 2008 Financial Results
  • May 8, 2008
    /C O R R E C T I O N -- Insmed Inc./
  • Apr 29, 2008
    Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
  • Apr 24, 2008
    Insmed to Host First Quarter 2008 Conference Call
  • Apr 22, 2008
    Insmed to Present at CBI Follow-On Biologics Conference
  • Apr 16, 2008
    Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
  • Apr 10, 2008
    Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
  • Mar 8, 2008
    Insmed Announces Additional Information in Compliance With NASDAQ Rules
  • Mar 4, 2008
    Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
  • Feb 28, 2008
    Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
  • Feb 19, 2008
    Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
  • Feb 11, 2008
    Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
  • Feb 5, 2008
    Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
  • Feb 5, 2008
    Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
  • Jan 28, 2008
    Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
  • Jan 22, 2008
    Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market
  • Dec 18, 2007
    Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
  • Dec 12, 2007
    Insmed Awarded $2.1 Million by Muscular Dystrophy Association
  • Dec 6, 2007
    Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
  • Dec 6, 2007
    Insmed Appoints Dennis M. Lanfear to Board Of Directors
  • Dec 3, 2007
    Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications
Show 5102550100 per page
  • «
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy